Statement of Financial Activities for the Year Ended 31 October 2024 ## The Thalidomide |||||31.10.24|31.10.23| |---|---|---|---|---|---| |||Unrestricted|Restricted|Total|Total| |||fund|funds|funds|funds| ||Notes|£|£|£|£| |**INCOME AND ENDOWMENTS FROM**|||||| |Donations and legacies||10,002|1,574|11,576|2,691| |**Charitable activities**|||||| |Grant income||-|7,693|7,693|-| |Investment income|3|14,935|101|15,036|16,729| |Other income||14,614|-|14,614|13,910| |**Total**||39,551|9,368|48,919|33,330| |**EXPENDITURE ON**|||||| |**Charitable activities**|||||| |Staff costs||16,335|582|16,917|38,288| |Other charges||54,266|926|55,192|99,176| |**Total**||70,601|1,508|72,109|137,464| |Net gains/(losses) on investments||44,291|-|44,291|(33,956 )| |**NET INCOME/(EXPENDITURE)**||13,241|7,860|21,101|(138,090 )| |**Transfers between funds**|10|(1,899 )|1,899|-|-| |**Net movement in funds**||11,342|9,759|21,101|(138,090 )| |**RECONCILIATION OF FUNDS**|||||| |Total funds brought forward||404,611|8,509|413,120|551,210| |**TOTAL FUNDS CARRIED FORWARD**||415,953|18,268|434,221|413,120| The notes form part of these financial Page The Thalidomide ## Balance Sheet 31 October 2024 |Unrestricted
Notes
fund
£
**CURRENT ASSETS**
Debtors
7
14,749
Investments
8
386,714
Cash at bank
16,794
418,257
**CREDITORS**
Amounts falling due within one year
9
(2,304 )
**NET CURRENT ASSETS**
415,953
**TOTAL ASSETS LESS CURRENT**
**LIABILITIES**
415,953
**NET ASSETS**
415,953
**FUNDS**
Unrestricted funds
10
Restricted funds
**TOTAL FUNDS**|Restricted
funds
£
-
-
18,268
18,268
-
18,268
18,268
18,268|31.10.24
Total
funds
£
14,749
386,714
35,062
436,525
(2,304 )
434,221
434,221
434,221
415,953
18,268
434,221|31.10.23
Total
funds
£
1,183
373,278
41,185
415,646
(2,526 )
413,120
413,120
413,120
404,611
8,509
413,120| |---|---|---|---| The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 October 2024. The members have not required the company to obtain an audit of its financial statements for the year ended 31 October 2024 in accordance with Section 476 of the Companies Act 2006. The trustees acknowledge their responsibilities for - (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and - (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company. The notes form part of these financial continued. Page ## The Thalidomide These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime. The financial statements were approved by the Board of Trustees and authorised for issue on .....15/03/2025....................... and were signed on its behalf by: The notes form part of these financial continued. Page The Thalidomide Balance Sheet - continued 31 October D Mansell D. Mansell Mr D Mansell - Trustee The notes form part of these financial Page The Thalidomide Notes to the Financial Statements for the Year Ended ## **1.** GENERAL INFORMATION The Thalidomide Society is a Charitable Incorporated Organisation (CIO). Its principal activity is to work with thalidomide and similarly impaired people, their families and supporters, providing a social network for thalidomide and similarly impaired people. Its registered office is Flat 29, Weymouth House, Hill House Mews, Bromley, BR2 0DD ## Company Status The charity is a Charitable Incorporated Organisation (CIO). It is registered on Companies House with the company number CE018092 but is not required to submit and accounts or other documents with them. The company is registered with The Charity Commission with the charity number the 231708. It is required to file an annual report with them which includes a copy of these accounts. ## **2.** ACCOUNTING POLICIES ## Basis of preparing the financial statements The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention. ## Income All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably. ## Expenditure Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources. ## Taxation The charity is exempt from corporation tax on its charitable activities. ## Fund accounting Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees. continued. Page 10 The Thalidomide ## Notes to the Financial ## Statements for the Year Ended Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes. Further explanation of the nature and purpose of each fund is included in the notes to the financial statements. ## Pension costs and other post-retirement benefits The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate. ## Debtors Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid. continued. Page 11 The Thalidomide Notes to the Financial Statements - continued for the Year Ended 31 ## **2.** ACCOUNTING POLICIES - continued Cash at bank ## and in hand Cash at bank and in hand includes cash and short-term liquid investments with a short maturity of 3 months or less from the date of acquisition or opening of the deposit or similar account. ## Liabilities Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. ## **3.** |INVESTMENT|31.10.24|31.10.23| |---|---|---| ||£|£| |INCOME||| |Investment income|15,036|16,729| ## **4.** TRUSTEES' REMUNERATION AND BENEFITS There were no trustees' remuneration or other benefits for the year ended 31 October 2024 nor for the year ended 31 October 2023. ## Trustees' expenses During the year some trustees were paid expenses to cover travel costs. The amount of these payments made were £1,098 (2023 - £1,068). ## **5.** |STAFF|31.10.24|31.10.23| |---|---|---| ||£|£| |COSTS||| |Wages and salaries|13,602|32,068| |Other pension costs|1,089|1,084| ||14,691|33,152| The average monthly number of employees during the year was as follows: continued. Page 12 The Thalidomide 31.10.24 31.10.23 1 2 Employees Notes to the Financial Statements - continued for the Year Ended 31 No employees received emoluments in excess of £60,000. continued. Page 13 The Thalidomide ## Notes to the Financial Statements - continued for the Year Ended 31 ## **6.** COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES |**6.**|COMPARATIVES FOR THE STATE
ACTIVITIES|ENT OF|FINANC|IAL| |---|---|---|---|---| |||Unrestricted|Restricted|Total| |||fund|funds|funds| |||£|£|£| ||**INCOME AND ENDOWMENTS FROM**|||| ||Donations and legacies|90|2,601|2,691| ||Investment income|16,681|48|16,729| ||Other income|13,910|-|13,910| ||**Total**|30,681|2,649|33,330| ||**EXPENDITURE ON**|||| ||**Charitable activities**|||| ||Staff costs|29,072|9,216|38,288| ||Other charges|84,461|14,715|99,176| ||**Total**|113,533|23,931|137,464| ||Net gains/(losses) on investments|(33,956 )|-|(33,956 )| ||**NET INCOME/(EXPENDITURE)**|(116,808 )|(21,282 )|(138,090 )| ||**Transfers between funds**|(8,000 )|8,000|-| ||**Net movement in funds**|(124,808 )|(13,282 )|(138,090 )| ||**RECONCILIATION OF FUNDS**|||| ||Total funds brought forward|529,419|21,791|551,210| ||**TOTAL FUNDS CARRIED FORWARD**|404,611|8,509|413,120| |**7.**|**DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**|||| ||||31.10.24|31.10.23| ||||£|£| ||PAYE & NI debtor
Prepayments and accrued income||1,183
~~13,566~~|1,183
~~-~~| ||||14,749|1,183| continued. Page 14 The Thalidomide Notes to the Financial Statements - continued for the Year Ended 31 |**8.**
**CURRENT ASSET INVESTMENTS**
Listed investments
**9.**
**CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**
Pension creditor
Accruals and deferred income
**10.**
**MOVEMENT IN FUNDS**
At
1.11.23
£
**Unrestricted funds**
General fund
404,611
**Restricted funds**
Thalidomide Society Oral History
13,506
Srey Hang & Beyond
4,595
HLF
(9,592 )
8,509
**TOTAL FUNDS**
413,120
Net movement in funds, included in the above are as follows:
Incoming
resources
£
**Unrestricted funds**
General fund
39,551
**Restricted funds**
Thalidomide Society Oral History
1,619
Srey Hang & Beyond
56
HLF
7,693
9,368
**TOTAL FUNDS**
48,919|Net
movement
in funds
£
13,241
111
56
7,693
7,860
21,101
Resources
expended
£
(70,601 )
(1,508 )
-
-
(1,508 )
(72,109 )||31.10.24
£
386,714
31.10.24
£
109
2,195
2,304
Transfers
between
funds
£
(1,899 )
-
-
1,899
1,899
-
Gains and
losses
£
44,291
-
-
-
-
44,291|31.10.23
£
373,278
31.10.23
£
78
2,448
2,526
At
31.10.24
£
415,953
13,617
4,651
-
18,268
434,221
Movement
in funds
£
13,241
111
56
7,693
7,860
21,101| |---|---|---|---|---| |||||| Page 15 continued. The Thalidomide Notes to the Financial Statements - continued for the Year Ended 31 ## **10. MOVEMENT IN FUNDS - continued** ## **Comparatives for movement in funds** |**Unrestricted funds**
General fund
**Restricted funds**
Thalidomide Society Oral History
Support for Srey Hang
HLF
**TOTAL FUNDS**|At
1.11.22
£
529,419
10,898
4,556
6,337
21,791
551,210|Net
movement
in funds
£
(116,808 )
2,608
39
(23,929 )
(21,282 )
(138,090 )|Transfers
between
funds
£
(8,000 )
-
-
8,000
8,000
-|At
31.10.23
£
404,611
13,506
4,595
(9,592 )
8,509
413,120| |---|---|---|---|---| Comparative net movement in funds, included in the above are as follows: |**Unrestricted funds**
General fund
**Restricted funds**
Thalidomide Society Oral History
Support for Srey Hang
HLF
**TOTAL FUNDS**|Incoming
resources
£
30,681
2,608
39
2
2,649
33,330|Resources
expended
£
(113,533 )
-
-
(23,931 )
(23,931 )
(137,464 )|Gains and
losses
£
Movement
in funds
£
(33,956 )
(116,808 )
-
2,608
-
39
-
(23,929 )
-
(21,282 )
(33,956 )
(138,090 )| |---|---|---|---| ## **11. RELATED PARTY DISCLOSURES** There were no related party transactions for the year ended 31 October 2024. Page 16 The Thalidomide ## Detailed Statement of Financial |Detailed Statement of Financial||| |---|---|---| |Activities for the Year Ended 31||| ||31.10.24|31.10.23| ||£|£| |**INCOME AND ENDOWMENTS**||| |**Donations and legacies**||| |Donations|10,003|1,191| |Lottery income|1,573|1,500| ||11,576|2,691| |**Investment income**||| |Investment income|15,036|16,729| |**Charitable activities**||| |Grants|7,693|-| |**Other income**||| |Delgate fees|14,614|13,910| |**Total incoming resources**|48,919|33,330| |**EXPENDITURE**||| |**Support costs**||| |**Human resources**||| |Wages|13,602|32,068| |Pensions|1,089|1,084| |Travel and subsistence costs|2,226|5,136| ||16,917|38,288| |**Other**||| |Insurance|96|254| |Telephone and communications|445|726| |Postage and stationery|609|260| |Computer and IT expenses|977|1,677| |Training seminars & workshops|44,278|78,207| |Oral history photography costs|-|7,946| |Oral history transcribing costs|-|4,243| |Memberships and subscriptions|95|-| |Repairs and renewals|-|1,198| |Recruitment costs|-|633| |Gifts|71|-| |Website development|4,560|-| |Investment fees|856|1,137| |Carried forward|51,987|96,281| This page does not form part of the statutory financial Page 17 The Thalidomide ## Detailed Statement of Financial |Detailed Statement of Financial||| |---|---|---| |Activities for the Year Ended 31||| ||31.10.24|31.10.23| ||£|£| |**Other**||| |Brought forward|51,987|96,281| |Accountancy fees|2,130|2,034| |Legal fees|1,075|861| ||55,192|99,176| |Total resources expended|72,109|137,464| |**Net expenditure before gains and losses**|(23,190 )|(104,134 )| |**Realised recognised gains and losses**||| |Realised gains/(losses) on fixed asset investments|44,291|(33,956 )| |**Net income/(expenditure)**|21,101|(138,090 )| This page does not form part of the statutory financial Page 18